Exanta “Not Approvable” Decision Leads To $80 mil. Charge
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca has taken an $80 mil. charge against half the assets associated with Exanta following FDA's "not approvable" decision